EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature
Ran Zeng, Lifeng Luo, Xianwen Sun, Zhiyao Bao, Wei Du, Ranran Dai, Wei Tang, Beili Gao, Yi Xiang
Abstract
mutation, consistent with the review of the literature (eight cases). Additionally, our case highlights the important role of sample type, method, and platform of gene detection in patient management, life quality, and prognosis, as well as the understanding of acquired resistance mechanism.
Topics & Concepts
TrametinibOsimertinibDabrafenibCancer researchMEK inhibitorMutationMedicineLung cancerEpidermal growth factor receptorV600EAdenocarcinomaOncologyCancerMAPK/ERK pathwayInternal medicineKinaseBiologyVemurafenibMelanomaGeneErlotinibGeneticsMetastatic melanomaLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysColorectal Cancer Treatments and Studies